-
Company Profile
LadRx Corp – Company Profile
LadRx Corp (LadRx ) formerly CytRx, is a biopharmaceutical company that focuses on the discovery and development of new therapeutics for the treatment of cancer and neurodegenerative diseases. LadRx’s product candidate, aldoxorubicin, is in the late stage of clinical development, and finds application in treating relapsed soft tissue melanoma, small-cell lung cancer, and other types of cancer with unmet medical needs. The company also has other pipeline products being developed through linker activated drug release technology platform. It has milestone...
Add to Basket -
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Non-Small Cell Lung Cancer Market Report Overview The non-small cell lung cancer (NSCLC) market size for the 15 markets (15M) was $30.7 billion in 2021. This included both Cell & gene therapies (CGTs) and established/traditional therapies. Cell therapies, consisting mostly of tumor-infiltrating lymphocytes (TILs) and CAR-T cells, are the most-abundant modality type in the NSCLC CGT pipeline but fall far behind traditional therapies such as monoclonal antibodies and small molecules. The non-small cell lung cancer market research report includes an...